Skip to main content

Evaluation of Cholangiocarcinomas (CCA) by Next Generation Sequencing (NGS) Reveals Frequent Actionable Genomic Abnormalities and New Routes to Targeted Therapies

Publication ,  Conference
Al-Rohil, R; Rand, JV; Jones, DM; Lee, HJ; Sheehan, CE; Otto, G; Palmer, G; Yelensky, R; Lipson, D; White, E; Balasubramanian, S; Garcia, L ...
Published in: LABORATORY INVESTIGATION
February 1, 2013

Duke Scholars

Published In

LABORATORY INVESTIGATION

ISSN

0023-6837

Publication Date

February 1, 2013

Volume

93

Start / End Page

397A / 397A

Location

Baltimore, MD

Publisher

NATURE PUBLISHING GROUP

Conference Name

102nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP)

Related Subject Headings

  • Pathology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Al-Rohil, R., Rand, J. V., Jones, D. M., Lee, H. J., Sheehan, C. E., Otto, G., … Ross, J. S. (2013). Evaluation of Cholangiocarcinomas (CCA) by Next Generation Sequencing (NGS) Reveals Frequent Actionable Genomic Abnormalities and New Routes to Targeted Therapies. In LABORATORY INVESTIGATION (Vol. 93, pp. 397A-397A). Baltimore, MD: NATURE PUBLISHING GROUP.
Al-Rohil, R., J. V. Rand, D. M. Jones, H. J. Lee, C. E. Sheehan, G. Otto, G. Palmer, et al. “Evaluation of Cholangiocarcinomas (CCA) by Next Generation Sequencing (NGS) Reveals Frequent Actionable Genomic Abnormalities and New Routes to Targeted Therapies.” In LABORATORY INVESTIGATION, 93:397A-397A. NATURE PUBLISHING GROUP, 2013.
Al-Rohil R, Rand JV, Jones DM, Lee HJ, Sheehan CE, Otto G, et al. Evaluation of Cholangiocarcinomas (CCA) by Next Generation Sequencing (NGS) Reveals Frequent Actionable Genomic Abnormalities and New Routes to Targeted Therapies. In: LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP; 2013. p. 397A-397A.
Al-Rohil, R., et al. “Evaluation of Cholangiocarcinomas (CCA) by Next Generation Sequencing (NGS) Reveals Frequent Actionable Genomic Abnormalities and New Routes to Targeted Therapies.” LABORATORY INVESTIGATION, vol. 93, NATURE PUBLISHING GROUP, 2013, pp. 397A-397A.
Al-Rohil R, Rand JV, Jones DM, Lee HJ, Sheehan CE, Otto G, Palmer G, Yelensky R, Lipson D, White E, Balasubramanian S, Garcia L, Mahoney K, Richards T, Terzic S, Banning V, Curran J, Downing S, Miller V, Stephens P, Ross JS. Evaluation of Cholangiocarcinomas (CCA) by Next Generation Sequencing (NGS) Reveals Frequent Actionable Genomic Abnormalities and New Routes to Targeted Therapies. LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP; 2013. p. 397A-397A.

Published In

LABORATORY INVESTIGATION

ISSN

0023-6837

Publication Date

February 1, 2013

Volume

93

Start / End Page

397A / 397A

Location

Baltimore, MD

Publisher

NATURE PUBLISHING GROUP

Conference Name

102nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP)

Related Subject Headings

  • Pathology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences